Skip to main content

Table 3 Analysis of association of gout risk with lipid and apo B-associated traits in study sample sets

From: The relationship of apolipoprotein B and very low density lipoprotein triglyceride with hyperuricemia and gout

 

NU vs. Gout

 

HU vs. Gout

 

Unadjusted OR [95% CI]

P

Adjusted OR [95% CI]

P

Unadjusted OR [95% CI]

P

Adjusted OR [95% CI]

P

Total Tg (mmol/L)

        

Europeans

2.34 [1.22-4.49]

0.011

1.37 [0.70-2.65]

0.36

1.21 [0.73-1.99]

0.46

1.31 [0.72-2.40]

0.38

Polynesians

1.41 [1.00-1.98]

0.049

1.00 [0.51-1.98]

0.99

1.17 [0.85-1.62]

0.34

1.14 [0.75-1.75]

0.54

Combined

1.59 [1.17-2.17]

0.003

1.19 [0.80-1.75]

0.39

1.18 [0.90-1.54]

0.24

1.20 [0.88-1.65]

0.25

Total FPLC Tg (mmol/L)

        

Europeans

4.17 [1.51-11.51]

0.006

1.97 [0.75-5.15]

0.17

4.37 [1.49-12.81]

0.007

5.19 [1.39-19.33]

0.014

Polynesians

1.29 [0.80-2.10]

0.30

0.65 [0.28-1.50]

0.31

1.51 [0.82-2.78]

0.19

1.52 [0.68-3.41]

0.31

Combined

1.74 [1.14-2.64]

0.01

1.17 [0.69-1.96]

0.56

2.05 [1.23-3.42]

0.006

2.14 [1.17-3.90]

0.014

VLDL Tg (mmol/L)

        

Europeans

11.29 [2.40-53.00]

0.002

3.24 [0.87-12.07]

0.080

6.52 [1.70-24.99]

0.006

7.61 [1.60-36.26]

0.011

Polynesians

1.92 [1.01-3.67]

0.048

0.98 [0.34-2.81]

0.97

2.46 [1.11-5.44]

0.026

2.84 [0.92-8.76]

0.069

Combined

2.78 [1.55-4.99]

0.001

1.81 [0.87-3.75]

0.11

3.19 [1.62-6.24]

0.001

3.56 [1.60-7.92]

0.002

Total apoB ( μmol/L)

        

Europeans

0.97 [0.36-2.63]

0.95

0.83 [0.18-3.76]

0.81

2.71 [0.94-7.76]

0.064

3.32 [0.87-12.61]

0.078

Polynesians

0.47 [0.18-1.23]

0.12

0.27 [0.04-1.73]

0.17

13.38 [1.48-120.76]

0.021

33.55 [1.16-972.93]

0.041

Combined

0.65 [0.34-1.26]

0.20

0.78 [0.32-1.93]

0.59

3.60 [1.41-9.17]

0.007

5.60 [1.73-18.18]

0.004

VLDL apo B (0.1 μmol/L)

        

Europeans

17.80 [2.99-106.02]

0.002

10.05 [1.16-87.35]

0.036

1.69 [0.74-3.86]

0.21

1.67 [0.62-4.51]

0.31

Polynesians

2.24 [0.89-5.60]

0.086

1.97 [0.48-8.12]

0.35

1.51 [0.61-3.73]

0.38

2.42 [0.70-8.36]

0.16

Combined

4.23 [1.87-9.59]

0.001

2.68 [1.03-6.95]

0.043

1.60 [0.87-2.93]

0.13

1.57 [0.80-3.09]

0.19

VLDL Tg:VLDL apo B

        

Europeans

1.06 [0.97-1.16]

0.20

1.02 [0.90-1.16]

0.78

1.06 [0.97-1.17]

0.20

1.02 [0.91-1.15]

0.68

Polynesians

1.05 [0.99-1.10]

0.086

1.03 [0.99-1.07]

0.19

1.08 [1.01-1.15]

0.024

1.08 [0.99-1.18]

0.061

Combined

1.04 [1.00-1.09]

0.051

1.03 [0.99-1.06]

0.15

1.06 [1.01-1.12]

0.016

1.06 [1.00-1.12]

0.045

  1. Adjusted for age, BMI, type 2 diabetes, SSB intake (drinks/day), alcohol intake (drinks/week), eGFR, hypertension and prescription of lipid-lowering medication. The Polynesian data are also adjusted by number of self-reported Polynesian grandparents. The combined analysis was additionally adjusted by ancestral group. NU: normouricaemia; HU: hyperuricaemia; OR: odds ratio; CI: confidence interval; Tg: triglyceride; FPLC: fast protein liquid chromatography; VLDL: very low-density lipoprotein; apo B: apolipoprotein B; BMI, body mass index; SSB: sugar-sweetened beverage; eGRF: estimated glomerular filtration rate.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us